

**PENNSYLVANIA DEPARTMENT OF PUBLIC WELFARE**  
**Pharmacy & Therapeutics Committee Minutes**  
**November 7<sup>th</sup>, 2017**

**Committee Members Present:**

Ivonne Acrich, M.D.	Ad Hoc Child/Adolescent Psychiatrist
Cheston Berlin, Jr., M.D	Pediatrician
Christopher Casella, Pharm. D.	Health Partners of Philadelphia Pharmacist
Terri Cathers, Pharm.D.,Chair	OMAP Pharmacy Director
Sharon Connor, Pharm.D.	Academic Pharmacist
Jessica Daw, Pharm.D.	UPMC For You Pharmacist
Donald Gerhart, R.Ph.	Community Pharmacist
Heather Gross, Pharm.D.	Aetna Clinical Pharmacist
James Hancovsky, R.Ph., MBA	United Health Care Pharmacy Director
David Haverstick, M.D.	Family Practitioner
David Kelley, M.D.	OMAP Chief Medical Officer
Jaymie Lako, R.Ph.	Gateway Health Plan Pharmacist
Andrew Maiorini, Pharm.D.	Keystone/AmeriHealth Perform Rx Clinical Pharmacist
Michele Musheno, R.Ph., M.S.	Academic/ Hospital Pharmacist
Ian Paul, M.D.	Pediatrician
Adam Raphael Rom, M.D.	Family Practitioner
James Schuster, M.D., Vice Chair	Psychiatrist
Kevin Szczecina, R.Ph.	Geisinger Health Plan Pharmacist
Andreas Wali, M.D.	Cardiologist
Lloyd Wertz	Consumer/Family Advocate

**Committee Members Not Present:**

Andrea Fox, M.D.	Internist
Rosemary Keffer, M.D.	Ad Hoc Adult Psychiatrist

**Public Testimony Heard by the Committee:**

Kelly Broderick (Sunovion) - Aptiom  
Debbie Smith (UCB) - Briviact  
Michael Boskello (Alkermes) - Aristada  
Phillip Jennings (Allergan) – Linzess, Saphris, Viberzi & Vraylar  
Steven Burch (Sunovion) – Seebri & Utibron  
Michael Raffaele (Sanofi Genzyme) - Kevzara  
Brian Stwalley (Bristol Meyers Squibb) - Orencia  
Jin Yun (Celgene) – Otezla  
Amy Hall (Novo Nordisk) – Tresiba, Victoza & Xultophy  
Mark Veerman (Janssen) – Invokana  
Howard Castillo (United Therapeutics) – Orenitram ER  
Lee Ann McDowell (Actelion) – Opsumit & Uptravi

<b>Welcome and Introduction</b>	Dr. Terri Cathers welcomed the Committee and the members introduced themselves.
<b>Approval of May 2017 Minutes</b>	The Committee approved the minutes from the May 2017 meeting without revision.
<b>Drug Class Reviews, Public Testimony, Discussion and Voting:</b>	
Androgenic Agents	The Committee reviewed the Androgenic Agents class and unanimously approved moving Androderm Patch and Methitest Tablets to preferred status.
Anticoagulants	The Committee reviewed and discussed the Anticoagulants class and unanimously approved moving enoxaparin syringes (labelers 63323 and 00955) to preferred status. As a result of this change, generic enoxaparin from all labelers will be preferred.
Anticonvulsants, Oral	The Committee reviewed the Anticonvulsants, Oral class and unanimously approved moving Banzel Suspension to preferred status.
Antidepressants	The Committee reviewed the Antidepressants, including the Antidepressants, Other and Antidepressants, SSRI PDL classes and unanimously approved adding desvenlafaxine extended release tablets to the PDL at non-preferred status.
Antiemetics/Antivertigo Agents	The Committee reviewed the Antiemetics/Antivertigo Agents class and unanimously approved adding Emend Suspension to the PDL at preferred status and adding aprepitant and Sustol Syringe to the PDL at non-preferred status.
Antihyperuricemics	The Committee reviewed the Antihyperuricemics class and unanimously approved moving colchicine capsules to preferred status, moving Mitigare to non-preferred status, and adding Zurampic to the PDL at non-preferred status.
Antiparkinson's Agents	The Committee reviewed the Antiparkinson's Agents class and unanimously approved adding Duopa and rasagiline to the PDL at non-preferred status.
Antipsychotics	The Committee reviewed the Antipsychotics class and unanimously approved moving Abilify Maintena to preferred status and adding quetiapine ER to the PDL at preferred status.
Anxiolytics	The Committee reviewed the Anxiolytics class. Dr. Kelley made a motion to move all forms of diazepam to non-preferred status citing health and safety concerns and limited utility of the medication. The Committee discussed long-acting benzodiazepines and their place in therapy. The Committee recognized the use of diazepam in seizure disorder. The Committee also discussed overutilization of benzodiazepines in light of the current opioid epidemic. After Committee discussion, Dr. Kelley withdrew his motion to move diazepam to non-preferred status and made a motion to have the DUR Board review diazepam utilization and consider possible utilization management strategies. The Committee unanimously approved the motion and did not recommend any changes to the class at this time.
Bronchodilators, Beta-Agonists	The Committee reviewed the Bronchodilators, Beta-Agonists class and unanimously approved moving Serevent Diskus to preferred status and moving Striverdi Respimat to non-preferred status.

COPD Agents	The Committee reviewed the COPD Agents class and unanimously approved moving Bevespi Aerosphere to preferred status, moving Anoro Ellipta, Combivent Respimat and Incruse Ellipta to non-preferred status, and adding Seebri Neohaler and Utibron Neohaler to the PDL at non-preferred status.
Cytokine and CAM Antagonists	The Committee reviewed the Cytokine and CAM Antagonists class and unanimously approved moving Cosentyx to preferred status with a step through Humira in the prior authorization guidelines, moving Enbrel to non-preferred status with grandfathering of beneficiaries currently on Enbrel, and adding Inflectra, Kevzara, Renflexis, Siliq and Tremfya to the PDL at non-preferred status.
Diabetic Meters	The Committee reviewed the Diabetic Meters class and unanimously approved moving True Metrix meters to preferred status and moving Abbott meters (Freestyle Lite, Freestyle Freedom Lite, Precision Xtra and Freestyle InsulinX) to non-preferred status.
Diabetic Strips	The Committee reviewed the Diabetic Strips class and unanimously approved moving True Metrix strips to preferred status and moving Abbott strips to non-preferred status.
GI Motility, Chronic Agents	The Committee reviewed the GI Motility, Chronic Agents class and approved moving Linzess to non-preferred status and adding Relistor Tablets and Trulance to the PDL at non-preferred status.
Glucocorticoids, Inhaled	The Committee reviewed the Glucocorticoids, Inhaled class and unaminously approved moving Pulmicort Flexhaler to preferred status, moving Asmanex Twisthaler and Qvar to non-preferred status, and adding Airduo Respiclick, Armonair Respiclick and fluticasone/salmeterol to the PDL at non-preferred status.
Growth Hormones	The Committee reviewed the Growth Hormones class and unaminously approved moving Genotropin to preferred status and moving Nutropin to non-preferred status.
Hepatitis C Agents	The Committee reviewed the Hepatitis C Agents class and unaminously approved adding Mavyret to the PDL at preferred status, moving Pegasys, Peginteron, Sovaldi, Technivie, Viekira Pak and Viekira XR to non-preferred status, and adding Vosevi to the PDL at non-preferred status. The Committee recognized the changing landscape within the Hepatitis C Agents class and identified that the proposed PDL changes ensure access to cost-effective evidence-based treatment options for MA beneficiaries.
Hypoglycemics, Insulin	The Committee reviewed the Hypoglycemics, Insulin class and unaminously approved moving Humulin R U-500 Kwikpen to preferred status, moving Novolin 70-30, Novolin N and Novolin R to non-preferred status, and adding Basaglar to the PDL at non-preferred status.
Hypoglycemics, Non-Insulin	The Committee reviewed Non-Insulin Hypoglycemic products, including the following PDL classes: Alpha-Glucosidase Inhibitors, Incretin Mimetics/Enhancers, Meglitinides, Metformins, SGLT2 Inhibitors, Sulfonylureas and TZDs. The Committee unaminously approved moving Farxiga, Glyxambi, Janumet, Januvia, Jardiance, Synjardy, and Xigduo XR to preferred status and moving Byetta, Invokana, Kombiglyze XR, metformin ER (generic Glumetza) and Onglyza to non-preferred status. The Committee also recommended adding Jentaduo XR and Synjardy XR to the PDL at preferred status and adding Invokamet XR, miglitol, Adlyxin, Soliqua and Xultophy to the PDL at non-preferred status.
Intranasal Rhinitis Agents	The Committee reviewed the Intranasal Rhinitis Agents class and unanimously approved moving budesonide, Cromolyn Sodium and Dymista to preferred status.

Leukotriene Modifiers	The Committee reviewed the Leukotriene Modifiers class and unanimously approved adding Zileuton ER to the PDL at non-preferred status.
Macular Degeneration Agents	The Committee reviewed the Macular Degeneration Agents class and unanimously approved no changes to the class.
Multiple Sclerosis Agents	The Committee reviewed the Multiple Sclerosis Agents class and unaminously approved moving Gilenya to preferred status, moving Aubagio to non-preferred status, adding Tysabri to the PDL at preferred status and adding Ocrevus and Zinbryta to the PDL at non-preferred status. Department staff reported that the recommendations were reviewed with a Multiple Sclerosis specialist at Geisinger Health System, Dr Neil Holland. Dr. Holland is the Director of Neurology for Geisinger Health System and agreed with the recommendations as presented. Dr. Holland did not have any conflicts of interest to disclose.
Ophthalmics for Allergic Conjunctivitis	The Committee reviewed the Ophthalmics for Allergic Conjunctivitis class and unanimously approved moving Pazeo to preferred status, moving olopatadine 0.1% to non-preferred status, and adding olopatadine 0.2% to the PDL at non-preferred status.
Ophthalmics, Anti-Inflammatories	The Committee reviewed the Ophthalmics, Anti-Inflammatories class and unanimously approved adding Bromsite to the PDL at non-preferred status.
Ophthalmic Immunomodulators	The Committee reviewed the Ophthalmic Immunomodulators class and unanimously approved making no changes to the class.
Opiate Dependence Treatments	The Committee reviewed the Opiate Dependence Treatments class and unanimously approved adding Probuphine Implant to the PDL at non-preferred status.
Otic Anti-Infectives	The Committee reviewed the Otic Anti-Infectives class and unanimously approved moving ofloxacin drops to preferred status, moving to ciprofloxacin to non-preferred status, and adding Floxin and Otovel to the PDL at non-preferred status.
Pulmonary Arterial Hypertension (PAH) Agents, Oral and Inhaled	The Committee reviewed the Pulmonary Arterial Hypertension (PAH) Agents, Oral and Inhaled class and unanimously approved moving Tracleer to preferred status.
Pancreatic Enzymes	The Committee reviewed the Pancreatic Enzymes class and unanimously approved making no changes to the class.
Phosphate Binders	The Committee reviewed the Phosphate Binders class and unanimously approved moving Calphron and Phoslyra Solution to preferred status.
Platelet Aggregation Inhibitors	The Committee reviewed the Platelet Aggregation Inhibitors class and unanimously approved adding aspirin-dipyridamole ER, Durlaza and Yosprala to the PDL at non-preferred status.
Progestational Agents	The Committee reviewed the Progestational Agents class and unanimously approved moving progesterone vial to preferred status and adding Endometrin to the PDL at non-preferred status.
Smoking Cessation Agents	The Committee reviewed the Smoking Cessation Agents class unanimously approved no changes to this class.
Stimulants and Related Agents	The Committee reviewed the Stimulants and Related Agents class and unanimously approved moving dextroamphetamine ER capsules and Quillichew ER to preferred status and adding armodafinil to the PDL at preferred status.

Ulcerative Colitis Agents	The Committee reviewed the Ulcerative Colitis Agents class and unanimously approved moving balsalazide to preferred status and adding mesalamine DR and Rowasa Enema kit to the PDL at non-preferred status.
"No Change Drug Classes"	<p>The Committee unanimously approved making no changes to the following classes:</p> <ul style="list-style-type: none"> <li>Alzheimer's Agents</li> <li>Anti-Allergens, Oral</li> <li>Antihistamines, Minimally Sedating</li> <li>Growth Factors</li> <li>H. Pylori Treatments</li> <li>Histamine II Receptor Blockers</li> <li>Methotrexate</li> <li>Ophthalmic, Antibiotics</li> <li>Ophthalmic, Antibiotic-Steroid Combinations</li> <li>Ophthalmics for Glaucoma</li> <li>Opiate Overdose Agents</li> <li>Proton Pump Inhibitors (PPIs)</li> <li>Sedative Hypnotics</li> </ul>
<b>Meeting Adjourned</b>	Dr. Cathers thanked the Committee for their participation and adjourned the meeting.